ARCH Venture Partners X, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1782583. 4 Form 4 filings on record with FilingPulse; latest filed 2025-10-29.
Transaction summary — filings shown
Covers all 4 filings on record, filed 2024-02-12 to 2025-10-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 4 filings — 9,964,181 shares, $44,999,962 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 3,200,000 shares @ $6.25 ($20,000,000) in Prime Medicine, Inc., filed 2024-02-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 10% owner | 2 | 2 legs · 6,230,300 sh · $29,999,990 | — | — |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | 3 legs · 1,818,181 sh · $9,999,996 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 1 | 1 leg · 1,915,700 sh · $4,999,977 | — | — |
Form 4 filings — ARCH Venture Partners X, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P. | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1782583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →